

28<sup>th</sup> November 2012

Dr Corinne Scott  
Administrator  
MREC for Wales  
6<sup>th</sup> Floor, Churchill House  
17 Churchill Way  
Cardiff  
CF10 2TW

Dear Dr Scott

**Re 08/MRE09/29 AML 17: A Programme of Development for the Treatment of Younger Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome**

I would be grateful if an amendment to this trial could be considered at the MREC meeting to be held on 13<sup>th</sup> December 2012.

The issues are:

- 1) In June 2011 the AML17 randomisation was amended and approved from a five way randomisation to a 2 way randomisation, the paediatric community have since decided that no children under the age of 16 years will participate in the AML 17 trial therefore all reference to the children randomisation has been removed.
- 2) The CEP701/placebo treatment for eligible FLT3+ patients has reached its target accrual and therefore this randomisation arm has been closed to recruitment, details of the treatment have been removed.
- 3) The protocol provides for allogeneic transplantation for all adult patients who have an HLA-matched sibling or volunteer unrelated donor and who are designated to have a high risk score or a FLT3+/NPM1- genotype. Recent maturing data suggests that patients who have intermediate risk defined by the risk score who are >40 years will benefit from a Reduced Intensity allograft from a matched sibling donor. Patients who are not high risk or favourable risk (Core Binding Factor) leukaemias are defined as intermediate risk and will be randomised to the 3 versus 4 comparison. Patients in this group who are >40 years of age should be considered for a Reduced Intensity Allograft (RIC) transplant if fully matched sibling donor is available. Investigators will be informed about eligible patients.
- 4) The Data monitoring Committee and the Trial Steering Group recommended that the M-tor randomisation be closed and patients discontinue treatment as the Everolimus has shown little or no benefit.

The enclosed documentation indicates the relevant changes in a tracked changed version.


Please find enclosed the following documentation:

1. Notification of Amendment Form

2. Document which describes the amendment to the protocol entitled AML17 protocol amendments: Version 7.2 June 2012 to Version 8.0 October 2012 which details the changes made to the protocol.
3. AML17 Protocol Version 8 October 2012 changes highlighted
4. Adult Patient Information Sheet 1 version 7 November 2012
5. Adult Patient Information Sheet 2 version 6 November 2012

Thank you for your consideration,

Yours Sincerely

A handwritten signature in black ink, appearing to read 'Alan Burnett', with a horizontal line underneath.

Alan Burnett